<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03250117</url>
  </required_header>
  <id_info>
    <org_study_id>ROP-001</org_study_id>
    <nct_id>NCT03250117</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole</brief_title>
  <official_title>An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Titan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Titan Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects stable on L-Dopa and oral ropinirole will have their ropinirole replaced with the
      Ropinirole Implant(s). The Ropinirole Implant was designed using the ProNeuraâ„¢ implant
      technology where the implant is inserted under the skin. This study will measure how much
      ropinirole is released in the blood during 3 months of treatment, and evaluate the side
      effects of this new formulation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of ropinirole</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Area under the plasma drug concentration-time curve of ropinirole</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of N-despropyl ropinirole</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Area under the plasma drug concentration-time curve of N-despropyl ropinirole</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of 7-hydroxy ropinirole</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Area under the plasma drug concentration-time curve of 7-hydroxy ropinirole</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Requip; One Ropinirole Implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Requip; Two Ropinirole Implants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Requip; Three Ropinirole Implants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Requip; Four Ropinirole Implants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropinirole oral product</intervention_name>
    <description>oral immediate-release ropinirole</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>Requip</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropinirole Implant</intervention_name>
    <description>ropinirole hydrochloride/ethylene vinyl acetate</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Voluntarily provided informed consent

          -  Meet diagnostic criteria for idiopathic Parkinson's Disease

          -  On L-Dopa and oral ropinirole

          -  If female of child-bearing potential, willing to practice contraception from time of
             informed consent to Follow-Up Visit

        Key Exclusion Criteria:

          -  Pregnant, breastfeeding, or planning to become pregnant

          -  Active epilepsy within the past year

          -  Severe dementia or cognitive impairment

          -  Donated or lost &gt; 400 mL of blood within 1 month prior to Screening

          -  History of alcohol or substance use disorder within the prior 12 months

          -  Recent episodes of moderate to severe dizziness or syncope

          -  Definite or suspected hypersensitivity to ropinirole or ethylene vinyl acetate

          -  Used any other investigational drug within 60 days or 5 half-lives prior to Screening,
             or plan to take any such drug any time during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rekha Sathyanarayana</last_name>
    <role>Study Director</role>
    <affiliation>Titan Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Titan Pharmaceuticals</last_name>
    <phone>650-244-4990</phone>
    <email>ROP-001@titanpharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orlando, Florida</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-210-1157</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Farmington Hills, Michigan</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>248-957-8940</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kirkland, Washington</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>425-899-5385</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2017</study_first_submitted>
  <study_first_submitted_qc>August 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2017</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>Dyskinesia</keyword>
  <keyword>ropinirole</keyword>
  <keyword>implant</keyword>
  <keyword>ProNeura</keyword>
  <keyword>movement disorders</keyword>
  <keyword>dopamine agonist</keyword>
  <keyword>extended-release</keyword>
  <keyword>Parkinsonian disorders</keyword>
  <keyword>brain diseases</keyword>
  <keyword>central nervous system diseases</keyword>
  <keyword>Neurodegenerative Diseases</keyword>
  <keyword>Antiparkinson agents</keyword>
  <keyword>Anti-dyskinesia agents</keyword>
  <keyword>dopamine agents</keyword>
  <keyword>neurotransmitter agents</keyword>
  <keyword>REQUIP</keyword>
  <keyword>subdermal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Ropinirole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

